文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肿瘤侵袭前的早期肺鳞癌免疫逃逸。

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

机构信息

Department of Intensive Care and Thoracic Oncology, Jules Bordet Institute, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), ULB, Brussels, Belgium.

Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

出版信息

Nature. 2019 Jul;571(7766):570-575. doi: 10.1038/s41586-019-1330-0. Epub 2019 Jun 26.


DOI:10.1038/s41586-019-1330-0
PMID:31243362
Abstract

Early detection and treatment are critical for improving the outcome of patients with cancer. Understanding the largely uncharted biology of carcinogenesis requires deciphering molecular processes in premalignant lesions, and revealing the determinants of the intralesional immune reaction during cancer development. The adaptive immune response within tumours has previously been shown to be strongest at the earliest stage of carcinoma. Here we show that immune activation and immune escape occur before tumour invasion, and reveal the relevant immune biomarkers of the pre-invasive stages of carcinogenesis in the lung. We used gene-expression profiling and multispectral imaging to analyse a dataset of 9 morphological stages of the development of lung squamous cell carcinoma, which includes 122 well-annotated biopsies from 77 patients. We identified evolutionary trajectories of cancer and immune pathways that comprise (1) a linear increase in proliferation and DNA repair from normal to cancerous tissue; (2) a transitory increase of metabolism and early immune sensing, through the activation of resident immune cells, in low-grade pre-invasive lesions; (3) the activation of immune responses and immune escape through immune checkpoints and suppressive interleukins from high-grade pre-invasive lesions; and, ultimately, (4) the activation of the epithelial-mesenchymal transition in the invasive stage of cancer. We propose that carcinogenesis in the lung involves a dynamic co-evolution of pre-invasive bronchial cells and the immune response. These findings highlight the need to develop immune biomarkers for early detection as well as immunotherapy-based chemopreventive approaches for individuals who are at high risk of developing lung cancer.

摘要

早期发现和治疗对于改善癌症患者的预后至关重要。要了解致癌作用的大部分未知生物学特性,就需要解析癌前病变中的分子过程,并揭示癌症发展过程中肿瘤内免疫反应的决定因素。肿瘤内适应性免疫反应以前被认为在癌的最早阶段最强。在这里,我们表明免疫激活和免疫逃逸发生在肿瘤侵袭之前,并揭示了肺癌癌前阶段的相关免疫生物标志物。我们使用基因表达谱和多光谱成像分析了一个肺鳞状细胞癌发展的 9 个形态学阶段的数据集,该数据集包括 77 名患者的 122 个有明确注释的活检样本。我们确定了癌症和免疫途径的进化轨迹,包括:(1)从正常组织到癌变组织,增殖和 DNA 修复呈线性增加;(2)在低级别癌前病变中,通过激活常驻免疫细胞,代谢和早期免疫感应短暂增加;(3)在高级别癌前病变中,通过免疫检查点和抑制性白细胞介素激活免疫反应和免疫逃逸;最终,(4)在癌症侵袭阶段激活上皮-间充质转化。我们提出,肺部的癌变涉及到癌前支气管细胞和免疫反应的动态共同进化。这些发现强调了需要开发用于早期检测的免疫生物标志物,以及针对有发展为肺癌高风险的个体的基于免疫疗法的化学预防方法。

相似文献

[1]
Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Nature. 2019-6-26

[2]
The immune landscape during the tumorigenesis of cervical cancer.

Cancer Med. 2021-4

[3]
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.

Nat Commun. 2021-5-11

[4]
Untangling the evolutionary roots of lung cancer.

Nat Commun. 2019-7-5

[5]
Neoantigen-directed immune escape in lung cancer evolution.

Nature. 2019-3-20

[6]
Evasion before invasion: Pre-cancer immunosurveillance.

Oncoimmunology. 2021-4-25

[7]
Single-cell transcriptome analysis deciphers the CD74-mediated immune evasion and tumour growth in lung squamous cell carcinoma with chronic obstructive pulmonary disease.

Clin Transl Med. 2024-8

[8]
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.

Cancer Prev Res (Phila). 2014-5

[9]
Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.

Aging (Albany NY). 2021-5-11

[10]
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.

Cancer Med. 2021-1

引用本文的文献

[1]
IL-20 Subfamily Biological Effects: Mechanistic Insights and Therapeutic Perspectives in Cancer.

Int J Mol Sci. 2025-7-29

[2]
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer.

Oncoimmunology. 2025-12

[3]
Attention-based deep learning for analysis of pathology images and gene expression data in lung squamous premalignant lesions.

medRxiv. 2025-6-12

[4]
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.

J Thorac Oncol. 2025-6-3

[5]
Real-Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis.

Adv Sci (Weinh). 2025-8

[6]
3D modeling of colorectal cancer: the pivotal role of the extracellular matrix, stroma and immune modulation.

Front Genet. 2025-5-1

[7]
Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation.

Cancer Drug Resist. 2025-4-24

[8]
Aberrant basal cell clonal dynamics shape early lung carcinogenesis.

Science. 2025-6-12

[9]
A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma.

Nat Commun. 2025-4-4

[10]
SITC strategic vision: prevention, premalignant immunity, host and environmental factors.

J Immunother Cancer. 2025-3-28

本文引用的文献

[1]
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.

Nat Med. 2019-1-21

[2]
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Nat Rev Drug Discov. 2019-3

[3]
Evolution of Metastases in Space and Time under Immune Selection.

Cell. 2018-10-11

[4]
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med. 2018-9-25

[5]
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

N Engl J Med. 2018-4-16

[6]
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

N Engl J Med. 2018-4-16

[7]
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med. 2018-4-15

[8]
The biology and management of non-small cell lung cancer.

Nature. 2018-1-24

[9]
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med. 2016-2-24

[10]
Substantial contribution of extrinsic risk factors to cancer development.

Nature. 2016-1-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索